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Pregnancy in women with systemic lupus erythematosus (SLE) is associated with an increased risk of adverse maternal and fetal
outcomes. Here, we present a case of severe maternal morbidity in a 23-year-old primigravida with SLE and secondary Sjo¨gren’s
syndrome who experienced a life-threatening multisystem flare at 17 weeks of gestational age. She presented to the emergency
department complaining of cough with hemoptysis and shortness of breath. She developed hypoxic respiratory failure and was
admitted to the intensive care unit. Bronchoscopy confirmed diffuse alveolar hemorrhage. Physical exam and laboratory evaluation
were consistent with an active SLE flare, pancytopenia, and new-onset lupus nephritis. After counseling regarding disease severity,
poor prognosis, and recommendation for therapywith cytotoxic agents, she agreed to interruption of pregnancywhichwas achieved
by medical induction. Her course was further complicated by thrombotic microangiopathy and generalized tonic-clonic seizures
attributable to posterior reversible encephalopathy syndrome versus neuropsychiatric SLE. This case represents one of the most
extreme manifestations of lupus disease activity associated with pregnancy that has been reported in the literature and emphasizes
the importance of preconception evaluation and counseling and amultidisciplinary management approach in cases with a complex
and evolving clinical course.
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease that predominantly affects women of childbearing
age. Pregnancy in women with SLE is associated with
an increased risk of adverse maternal and fetal outcomes.
Here, we present a case of severe maternal morbidity in a
young woman with SLE and secondary Sjo¨gren’s syndrome
who experienced a life-threatening multisystem flare which
required a prolonged stay in the intensive care unit and inter-
ruption of pregnancy in the second trimester. Althoughmany
cases of life-threatening and even fatal maternal complica-
tions of SLE have been described in the literature, there are
few reported cases in which such a large number of different
organ systems are affected, as we describe here. With such an
uncertain and complex disease course, clinical management
can be very challenging, necessitating a multidisciplinary
approach to care.
2. Case Presentation
A 23-year-old primigravida at 17 weeks of gestational age
presented to the emergency department complaining of
worsening cough with intermittent hemoptysis, shortness
of breath, and chest pain which had been present for
several weeks and exacerbated by light physical activity.
Her past medical history was significant for SLE with sec-
ondary Sjo¨gren’s syndrome diagnosed 6 years before based
on findings of arthritis, malar rash, positive antinuclear
antibodies (ANA), elevated anti-double-strandedDNA (anti-
dsDNA), and the presence of anti-Ro/SSA antibodies. She
had no prior surgery and was not taking any medications.
She reported no SLE flares in the past few years and had
discontinued hydroxychloroquine (HCQ) approximately one
year earlier. Her obstetrician referred her for a maternal-
fetal medicine consultation in early pregnancy, at which time
she acknowledged that she was no longer under the care of
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Figure 1: Chest radiograph on the day of admission noted indistinct
increased markings and a patchy opacity in the right lower lung.
a rheumatologist. She did not receive any risk assessment
or counseling prior to conception. Two months prior to
pregnancy, her serum creatinine was 0.74mg/dL and her
systolic and diastolic blood pressures ranged from 100 to
120mm Hg and from 70 to 80mm Hg, respectively. Of note,
she was treated with antibiotics for pneumonia three times in
the past 14 months and was known to have a recent negative
purified protein derivative (PPD) skin test.
Upon arrival to the hospital, she was awake and alert
and in no apparent distress. Her heart rate was 116 beats per
minute. She was afebrile and normotensive with a respiratory
rate of 16 breaths per minute and an oxygen saturation
of 100% on room air. Abdominal exam noted a gravid,
nontender uterus. Her respiratory effort appeared normal
and her lungs were clear to auscultation. A subtle malar
rash and diffuse, white ulcerative plaques were visualized
on the buccal mucosa and palate. Bilateral lower extremity
pitting edema was noted. The physical exam was other-
wise unremarkable. Abdominal ultrasound demonstrated
an intrauterine pregnancy with a fetal heart rate of 150
beats per minute. Laboratory evaluation was significant
for a hemoglobin and hematocrit of 6.1 g/dL and 18.5%,
respectively.The white blood cell (WBC) count was 3,300/uL
and the platelet count was 101,000/uL. Serum creatinine
was 1.04mg/dL and urine protein/creatinine ratio was 4.7.
A 24-hour urine collection contained over 3 grams of
protein. Antiphospholipid antibody testing was performed.
On hospital day (HD) 1, anticardiolipin IgG and IgM were
24GPL and 8MPL, respectively, and repeat testing on HD2
yielded 34GPL and 11MPL, respectively (medium or high
titer typically defined as >40GPL or MPL). Anti-beta2-
glycoprotein I antibody screen was negative. Lupus antico-
agulant assays, which included dilute Russell viper venom
time (dRVVT) and silica clotting time (SCT), were nega-
tive. An electrocardiogram (EKG) showed sinus tachycardia.
Chest radiography featured indistinct increased markings
and a patchy opacity in the right lower lung (Figure 1).
Chest computed tomography angiography (CTA) found no
evidence of pulmonary embolism but did reveal a patchy
infiltrate in the right middle and lower lobes with small
bilateral pleural effusions and enlarged hilar lymph nodes
Figure 2: Chest computed tomography angiography (CTA) on the
day of admission noting patchy infiltrate in the right middle and
lower lung lobes and small bilateral pleural effusions.
(Figure 2). After initial evaluation by the obstetrical and
emergency medicine teams, consultations were requested
with pulmonology, infectious disease, rheumatology, hema-
tology, and nephrology to assist in further management. The
decision was made to admit the patient for treatment of sus-
pected community-acquired pneumonia (CAP), new-onset
nephrotic syndrome likely secondary to lupus nephritis, and
an active SLE flare associated with pancytopenia, malar rash,
oral ulcers, and lymphadenopathy.
The patient was started on intravenous ceftriaxone and
azithromycin for CAP and HCQ and pulse methylpred-
nisolone for the SLE flare. Thromboprophylaxis was initiated
with enoxaparin. She received a transfusion of two units of
packed red blood cells (PRBCs) for severe anemia described
as normocytic and direct coombs test positive. Indirect
bilirubin and lactate dehydrogenase (LDH) were increased,
serum haptoglobin was decreased, and a peripheral smear
showed a few schistocytes and some spherocytes; these
findings were most consistent with autoimmune hemolytic
anemia. Overall, her pancytopenia was thought to be multi-
factorial. In the coming days, there was evidence of continued
hemolysis despite steroid administration with a persistently
elevated LDH and low serum haptoglobin (<20mg/dL), as
well as repeat peripheral smears demonstrating numerous
schistocytes. Of note, a repeat direct coombs test was
negative. Collectively, these findings were concerning for
other (nonimmune) causes of hemolysis such as microan-
giopathic hemolytic anemia (MAHA) or thrombotic throm-
bocytopenic purpura (TTP). A normal ADAMTS13 activity
level subsequently ruled out the latter.
OnHD5, the patient was started on supplemental oxygen
via nasal cannula after it was noted that her oxygen saturation
on room air decreased to below 90%. Over the next few
days her oxygen requirements gradually increased to 6 L/min.
Pulmonary edema was suspected based on diffuse b-lines on
lung ultrasound and repeat chest radiographnoting increased
bilateral pleural effusions. All intravenous fluids were discon-
tinued, and furosemide was administered. Improvement in
lower extremity edema and good urine output were noted.
However, she continued to experience shortness of breath
with oxygen saturation as low as 80% on supplemental
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Figure 3: Repeat chest computed tomography angiography (CTA)
on hospital day 5 featuring progressive ground-glass opacities
bilaterally, which, in the setting of continued hemoptysis, was
concerning for diffuse alveolar hemorrhage.
oxygen. A repeat chest CTA noted progressive ground-
glass opacities bilaterally (Figure 3), which, in the setting of
continued hemoptysis, increased concern for diffuse alveolar
hemorrhage (DAH). On HD8 she was transferred to the
intensive care unit for worsening hypoxia despite diuresis,
antibiotic therapy, and steroids.Therapeutic plasma exchange
(TPE) was performed with a plan for 4 additional sessions.
Fiberoptic bronchoscopy with sequential bronchoalveolar
lavage (BAL) demonstrated grossly hemorrhagic fluid consis-
tent with DAH.
Given the severity of maternal disease, poor progno-
sis for the fetus, and recommendation for more aggres-
sive therapy, the patient was counseled for termination of
pregnancy. The patient understood that the risk of early-
onset preeclampsia and extreme preterm delivery was high
even if her pulmonary and renal status were to improve
significantly. She was induced and delivered vaginally on
HD10. Cyclophosphamide, an alkylating agent associated
with gonadal toxicity and teratogenicity, was administered
after a suboptimal response to steroids and TPE.
In the first few days after delivery, her blood pressures
were persistently elevated (≥140/90mm Hg) but generally
below severe range (160/110mmHg). A repeat 24-hour urine
collection onHD 14 was found to have a total protein of more
than 17 grams. Serum creatinine increased to 1.02mg/dL.
On HD22, a kidney biopsy was performed, which revealed
lupus nephritis, diffuse global proliferative type, class IV-G
(A), and an active thrombotic microangiopathy (TMA) in
several arterioles and glomerular vascular poles. The patient
was discharged home on HD25 on prednisone and HCQ for
lupus, losartan for hypertension, and furosemide for edema
associatedwith nephrotic syndrome. Shewas also to continue
cyclophosphamide infusions outpatient.
Less than two weeks after discharge, the patient was
readmitted with symptomatic anemia and progressive lower
extremity edema. She was also noted to have worsening
hypertension (systolic blood pressure 160–200mm Hg),
acute kidney injury (creatinine 1.7→ 2.5mg/dL), andworsen-
ing thrombocytopenia (platelet count 81,000 → 52,000/uL).
Serum LDH increased to 1,028U/L. These findings were
suspicious for an SLE flare-inducedTMAexacerbation versus
atypical hemolytic uremic syndrome (aHUS). Pulse dose
Figure 4: Brain magnetic resonance imaging (MRI) demonstrated
symmetrical bilateral hyperintensities on T2-weighted imaging and
fluid-attenuated inversion recovery (FLAIR) sequences consistent
with cerebrocortical edema.
steroids were again administered. Nicardipine infusion was
started for blood pressure optimization. Approximately one
hour after a transfusion of PRBCs was started, the patient
was found to have altered mental status. She then experi-
enced a series of generalized tonic-clonic seizures in quick
succession without recovery between episodes. This was
followed by a postictal state. Lorazepam and levetiracetam
were administered. She was intubated and mechanically
ventilated for airway protection and transferred to the ICU
for status epilepticus. Urgent brain MRI demonstrated sym-
metrical bilateral hyperintensities on T2-weighted imaging
and fluid-attenuated inversion recovery (FLAIR) sequences
consistent with cerebrocortical edema (Figure 4); there was
no evidence of acute infarct or hemorrhage. Neurology
was consulted. Posterior reversible encephalopathy syndrome
(PRES) and neuropsychiatric SLE (NPSLE) were highest
in the differential diagnosis. Eclampsia was thought less
likely at more than 3 weeks postpartum, after delivery of
a 17-week fetus. After an inadequate hematologic response
to pulse dose steroids, eculizumab, a monoclonal antibody
and complement inhibitor, was started. Over the next few
days, the platelet count and LDH began improving, sug-
gesting a response to this treatment. The patient received
a total of 5 units of PRBCs and 3 doses of eculizumab
and was successfully extubated on HD5 after readmission.
Repeat antiphospholipid antibody testing was performed.
Anticardiolipin IgG and IgM decreased to 4GPL and 3MPL,
respectively. Anti-beta2-glycoprotein I antibody screen and
lupus anticoagulant functional assays remained negative. She
was discharged home on HD13 on labetalol and amlodipine
for blood pressure control, HCQ and prednisone for lupus,
levetiracetam for seizure prophylaxis, and cefuroxime for
meningitis prophylaxis given that eculizumab increases sus-
ceptibility to Neisseria infection.
Over the next several months, she experienced continued
seizure activity and frequent headaches which required inter-
mittent hospitalization.
3. Discussion
It is well established that pregnant women with SLE have
an increased risk of adverse maternal and fetal outcomes,
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including, among others, preeclampsia, venous thromboem-
bolism, infection, unplanned cesarean delivery, fetal growth
restriction, preterm birth, and fetal loss [1]. In addition,
maternal mortality may be 20-fold higher in women with
SLE [2]. Active disease and lupus nephritis are nearly always
present in such cases, and the two major causes of death are
complications from lupus disease activity and opportunistic
infection [3].
Based on the numerous risks associated with pregnancy,
it is recommended that women with SLE have a precon-
ception evaluation and multidisciplinary management with
maternal-fetal medicine and rheumatology during preg-
nancy. Active SLE at the time of conception is a predictor
of adverse outcomes; it is suggested that the disease be
quiescent for six months prior to attempting pregnancy
[4]. Laboratory testing should, at a minimum, include
antiphospholipid antibodies (lupus anticoagulant, IgG and
IgM anticardiolipin antibodies, IgG and IgM anti-beta2-
glycoprotein I antibodies), anti-Ro/SSA and anti-La/SSB
antibodies, and an assessment of renal function (creatinine,
spot urine protein/creatinine ratio). Women who have anti-
Ro/SSA and anti-La/SSB antibodies should have intensive
fetal surveillance for heart block with weekly pulsed-Doppler
fetal echocardiography (to measure the mechanical PR inter-
val) starting at 16–18 weeks and continuing through 26–28
weeks of pregnancy. Ideally, all women with SLE should be
on HCQ and low-dose aspirin during pregnancy, unless oth-
erwise contraindicated. Women who continue HCQ during
pregnancy have fewer disease flares, improved outcomes, and,
in mothers with anti-Ro/SSA and anti-LA/SSB antibodies, a
reduced risk of fetal heart block [5]. Low-dose aspirin started
at 12–16 weeks of gestation reduces the risk of preeclampsia
and fetal growth restriction [6]. Discontinuation of med-
ications used to control disease activity increases the risk
of flares and associated pregnancy complications. Serial
ultrasound examinations should be performed to assess fetal
growth and antepartum fetal surveillance should be initiated
in the third trimester.
Renal involvement is common in patients with SLE and
may be suspected in the presence of proteinuria or an elevated
serum creatinine. Lupus nephritis is diagnosed and classified
based on histopathologic findings on renal biopsy [7]. Most
patients with this condition have an immune complex-
mediated glomerular disease. The most common and most
severe form of lupus nephritis is class IV, defined histologi-
cally as involvement of more than 50 percent of glomeruli on
light microscopy [8]. Class IV disease is further subclassified
based on whether affected glomeruli are segmentally (S) or
globally (G) affected and whether the inflammatory activity
of the lesions is active (A), chronic (C), or both (A/C).
Hypertension and nephrotic syndrome, consisting of heavy
proteinuria, hypoalbuminemia, and peripheral edema, are
often seen in active class IV disease and patients character-
istically have low complement levels (C3) and elevated anti-
dsDNA levels.
Involvement of the renal vasculature in cases of lupus
nephritis is a poor prognostic sign. In thrombotic microan-
giopathy (TMA), damage to the endothelial cells of small
arterioles and capillaries results inmicrovascular thrombosis.
Nearly all TMAs cause microangiopathic hemolytic ane-
mia (MAHA) and thrombocytopenia. MAHA results from
intravascular fragmentation of red blood cells, which pro-
duces schistocytes on peripheral blood smear.
Alveolar hemorrhage is a rare, life-threatening complica-
tion which occurs in approximately 0.5–3.7% of nonpregnant
SLE patients [9, 10] and has also been reported during
pregnancy in a limited number of case reports and case series
[11–13]. This is typically associated with active class III or IV
lupus nephritis and increased disease activity. Microvascular
injury is thought to result from immune complex deposition
in the alveolar wall with induction of apoptosis [14, 15]. The
mortality rate for SLE patients with DAHmay exceed 50% [9,
16]. It is important to recognize that hemoptysis is reported
in less than two-thirds of such cases [17]. More frequent
signs and symptoms are hypoxemia, dyspnea, cough, and
fever. Thus, DAH can easily be mistaken for pneumonia or
pulmonary edema [18]. In patients with lupus nephritis, clin-
ical suspicion for DAH should be increased in the presence
of acute pulmonary symptoms, new radiographic infiltrates,
and a falling hematocrit, even in the absence of hemopt-
ysis. The diagnosis is established by flexible bronchoscopy
with sequential BAL. Characteristically, lavage aliquots are
progressively more hemorrhagic and Prussian blue staining
reveals hemosiderin-containing macrophages [19, 20]. High
clinical suspicion, early diagnosis, and aggressive therapy
with glucocorticoids and cyclophosphamide are the corner-
stones of DAHmanagement in patients with SLE. Ventilatory
support and blood transfusion should be offered as necessary.
Although it is uncertain whether it improves survival, plasma
exchange therapy is frequently offered to remove circulating
immune complexes from the blood, especially in cases where
there is an inadequate clinical response to cyclophosphamide
[21].
Posterior reversible encephalopathy syndrome (PRES),
characterized by headache, visual disturbances, confusion,
and seizures, is an underrecognized condition associatedwith
SLE [22]. Pregnancy-related PRES in women without SLE
occurs most frequently in conjunction with preeclampsia-
eclampsia [23]. Disruption of the blood brain barrier sec-
ondary to endothelial dysfunction results in vasogenic
edema, often in the parietooccipital regions; this produces a
characteristic magnetic resonance imaging (MRI) finding of
hyperintense signal in affected areas on T2-weighted imaging
[24, 25]. At the time of presentation, most SLE patients
diagnosedwith PRES have hypertension, lupus nephritis, and
active disease with multiple complications [26, 27].
Although it is one of the most prevalent complications of
lupus, likely affecting the majority of patients at some time
in their disease course, NPSLE is arguably the most poorly
understood [28, 29]. NPSLE associated with pregnancy has
been addressed in scant case reports and case series [30, 31].
Nervous system involvement can produce a complex array
of neurological, psychiatric, and behavioral manifestations
that increase morbidity and mortality. The American Col-
lege of Rheumatology (ACR) has developed a standardized
nomenclature system which defines 19 NPSLE syndromes
involving the central and peripheral nervous systems [32].
Cognitive dysfunction, headaches, and psychiatric disorders
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are some of the most common NPSLE syndromes [29, 33].
In all cases, NPSLE is a diagnosis of exclusion; all other
possible etiologies of the observed neuropsychiatric symp-
toms must be considered and excluded, including electrolyte
abnormalities, infection, renal failure, and drug effects. In
the absence of a gold standard diagnostic test, this may
represent a significant clinical challenge, especially in preg-
nancy and the postpartum period, where pregnancy-specific
conditions such as preeclampsia-eclampsia may produce the
same symptoms.The pathogenesis of NPSLE is multifactorial
and involves inflammatory cytokines, autoantibodies, and
immune complexes that contribute to vasculopathic, cyto-
toxic, and autoantibody-mediated neuronal dysfunction [34].
Management remains empirical without any standardized,
evidence-based approach to treatment [35].
Antiphospholipid syndrome (APS) is an autoimmune
disorder characterized by vascular thromboses and/or preg-
nancy morbidity in the presence of persistent antiphospho-
lipid antibodies. A small subset of patients with APS (<1%)
develop multiple organ failure secondary to widespread
thrombotic disease, a condition referred to as catastrophic
APS (CAPS) which has a mortality rate of up to 50% [36].
A definitive diagnosis requires simultaneous involvement of
3 or more organs and histopathologic confirmation in at least
one organ or tissue. In the case described here, the patient
did not meet criteria for APS. She did have anticardiolipin
antibodies but at titers below the threshold to meet APS
laboratory criteria (>40GPL or MPL). However, the clinical
similarities with CAPS are worth noting. Although it is
possible that serial laboratory evaluation during her first
hospital admission would have yielded an anticardiolipin IgG
titer > 40GPL, the anticardiolipin results during her second
admission demonstrate that they were not persistent and,
therefore, not consistent with APS or CAPS.
Termination of pregnancy in the second trimester, prior
to viability, to preserve the health of the mother in cases
of severe SLE disease activity is infrequent and usually per-
formed to facilitate more aggressive treatment. Although the
physiologic changes of pregnancy, including an increase in
glomerular filtration rate and renal plasma flow, may worsen
preexisting renal disease, there is not sufficient evidence to
suggest that interruption of pregnancy, in and of itself, has
a beneficial effect on the resolution of an acute disease flare.
However, it is theoretically possible that a rapid decline in
pregnancy hormone levels, particularly estrogen, may be
advantageous [37]. Immunosuppressive medications used to
treat SLE, such as cyclophosphamide, are known to cross
the placenta and have teratogenic effects. In addition, this
particular medication has been associated with premature
and irreversible ovarian failure. It should only be offered, after
appropriate counseling, in cases where no alternative therapy
is available.
In the case presented here, the patient did not have many
of the known prepregnancy predictors of adverse pregnancy
outcomes. Specifically, she did not have any recent disease
exacerbations, antiphospholipid antibodies, thrombocytope-
nia, prior lupus nephritis, or prior use of antihypertensive
medications [1, 38]. However, as a primigravida, she was at
increased risk for flare during pregnancy [39]. In addition,
her discontinuation of HCQ prior to pregnancy, lack of
preconception counseling, and lapse in rheumatologic care
placed her at increased risk of pregnancy morbidity.
In summary, SLE disease flares can occur at any time dur-
ing pregnancy and with unpredictable severity. All women
with a diagnosis of SLE should be offered a preconception
evaluation and consultation, with a goal of reducing adverse
pregnancy outcomes through health education, risk assess-
ment, and appropriate interventions. In cases with a complex
and evolving clinical course, the importance of a collabo-
rative and multidisciplinary management approach must be
emphasized. Furthermore, it is essential that management
occur at a tertiary referral center with experience managing
critically ill high-risk obstetric patients.
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